Evidence map›Paper›PMID 37550911›Full record

ReviewCurrent medicinal chemistry2024

Drug Repurposing against Novel Therapeutic Targets in

Shweta Rai, Shruti Shukla, Luciana Scotti, Ashutosh Mani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shweta RaiDepartment of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad, 211004 India.
Shruti ShuklaDepartment of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad, 211004 India.
Luciana ScottiPostgraduate Programa in Natural and Synthetic Bioactive Compounds, University Hospital, Federal University of Paraíba-Campus I, 58051-970, João Pessoa, PB, Brazil.
Ashutosh ManiDepartment of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad, 211004 India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malaria remains one of the most challenging tropical diseases. Since malaria cases are reportedly alarming in terms of infections and mortality, urgent attention is needed for addressing the issues of drug resistance in falciparum malaria. High throughput screening methods have paved way for rapid identification of anti-malarial. Furthermore, drug repurposing helps in shortening the time required for drug safety approvals. Hence, discovery of new antimalarials by drug repurposing is a promising approach for combating the disease. This article summarizes the recent computational approaches used for identifying novel antimalarials by using drug target interaction tools followed by pharmacokinetic studies.

Indexed as

AntimalarialsDrug RepositioningMalaria, FalciparumPlasmodium falciparumHumansAntimalarialsantimalarialcomputational biologycomputational perspective.drug repurposingFalciparumtropical diseases

Identifiers

PMID37550911

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.